Record lev­els of VC fi­nanc­ing and R&D boom left bio­phar­ma com­pa­nies clam­or­ing for space. How bad is it?

There are mul­ti­ple ways to mea­sure just how vi­brant the life sci­ence in­dus­try is: the in­flux of ven­ture cap­i­tal (now re­treat­ing slight­ly from a record …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.